cagrilintide fda Novo Nordisk Submits CagriSema for FDA Approval for Obesity Treatment Cagrilintide 10mg Research Peptide |

[2] The Phase 3a REDEFINE 2 trial then tested once-weekly CagriSema (cagrilintide 2.4 mg plus semaglutide 2.4 mg) against placebo in 1,206 adults with obesity and type 2 diabetes over 68 weeks, reporting a mean bodyweight change of 13.7% versus 3.4% for placebo

Cagrilintide is a long-acting analog of amylin (islet amyloid polypeptide), a pancreatic hormone co-secreted with insulin that induces satiety

M., Mullally, J

By purchasing this product, you confirm that you are a qualified researcher and will use it in accordance with all applicable laws and regulations

Cagrilintides longer measured half-life (roughly 78 days versus about 5 days for tirzepatide) is a pharmacokinetic fact from its own study not evidence of a better outcome